JENKINTOWN, PA — The National Comprehensive Cancer Network (NCCN) announces the release of Chapters 4 and 5 of the NCCN Drugs & Biologics Compendium™: Acute Myeloid Leukemia and Chronic Myelogenous Leukemia.
“The NCCN Drugs & Biologics Compendium contains authoritative and definitive information about the appropriate use of drugs and biologics in the care of patients with leukemia – information that decision-makers at insurance and managed care companies and pharmacy benefits managers can use to establish coverage policy,” said William T. McGivney, Ph.D., CEO of the NCCN. “With the release of the leukemia chapters, NCCN utilization information adds to a long list of scientific, evaluative products to facilitate decision-making about appropriate cancer care.”
The NCCN Drugs & Biologics Compendium outlines the appropriate uses of drugs and biologics in the care of cancer patients, as derived from the NCCN Clinical Practice Guidelines in Oncology™ — recognized and applied nationally as the standard for clinical policy in oncology. Listed uses include FDA-approved indications as well as those beyond FDA labeling. As with the guidelines, the Compendium spans the continuum of cancer care from early stage to advanced stage disease, and from supportive to palliative care.
Oncology care professionals can visit www.nccn.org to access the most up-to-date version of the NCCN Drugs & Biologics Compendium online or to request a free printed copy.
For more information on the NCCN Drugs & Biologics Compendium and other NCCN programs, please contact NCCN at 215-690-0254 or at www.nccn.org.
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 23 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.